PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular cancer therapeutics"
DOI: 10.1158/1535-7163.mct-22-0217
Abstract: Alterations in the ATM gene are among the most common somatic and hereditary cancer mutations, and ATM-deficient tumors are hypersensitive to DNA damaging agents. A synthetic lethal combination of DNA damaging agents and DNA repair… read more here.
Keywords: atm deficient; deficient; deficient tumors; topoisomerase inhibitor ... See more keywords